Wedbush initiated coverage of Eikon Therapeutics (EIKN) with an Underperform rating and $7 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EIKN:
- Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
- Eikon Therapeutics completes IPO and updates governance documents
- Eikon Therapeutics opens at $17.05, IPO priced at $18.00
- Eikon Therapeutics indicated to open at $17.92, IPO priced at $18 per share
- Eikon Therapeutics 21.18M share IPO priced at $18.00